Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
BACKGROUND: Prostate cancer cells secrete unique proteases such as prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) that represent targets for the activation of prodrugs as systemic treatment of metastatic prostate cancer. Previously, a combinatorial peptide library was screen...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1797096248723898368 |
|---|---|
| author | Janssen, S Rosen, D Ricklis, R Dionne, C Lilja, H Christensen, S Isaacs, J Denmeade, SR |
| author_facet | Janssen, S Rosen, D Ricklis, R Dionne, C Lilja, H Christensen, S Isaacs, J Denmeade, SR |
| author_sort | Janssen, S |
| collection | OXFORD |
| description | BACKGROUND: Prostate cancer cells secrete unique proteases such as prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) that represent targets for the activation of prodrugs as systemic treatment of metastatic prostate cancer. Previously, a combinatorial peptide library was screened to identify a highly active peptide substrate for hK2. The peptide was coupled to an analog of the potent cytotoxin thapsigargin, L12ADT, to generate an hK2-activated prodrug that was efficiently hydrolyzed by purified hK2, stable to hydrolysis in human and mouse plasma in vitro and selectively toxic to hK2 producing prostate cancer cells in vitro. METHODS: In the current study, toxicology, pharmacokinetics, prodrug biodistribution, and antitumor efficacy studies were performed to evaluate the hK2-activated prodrug in vivo. RESULTS: The single intravenous maximally tolerated dose of prodrug was 6 mg/kg (i.e., 3.67 micromole/kg) which produced peak serum concentration of approximately 36 microM and had a half-life of approximately 40 min. In addition, over a 24 hr period <0.5% of free L12ADT analog was observed in plasma. The prodrug demonstrated significant antitumor effect in vivo while it was being administered, but prolonged intravenous administration was not possible due to local toxicity to tail veins. Subcutaneous administration of equimolar doses produced lower plasma AUC compared to intravenous dosing but equivalent intratumoral levels of prodrug following multiple doses. CONCLUSIONS: The hK2-activated prodrug was stable in vivo. The prodrug, however, was rapidly cleared and difficult to administer over prolonged dosing interval. Additional studies are underway to assess antitumor efficacy with prolonged administration of higher subcutaneous doses of prodrug. Second-generation hK2-activated thapsigargin prodrugs with increased half-lives and improved formulations are also under development. |
| first_indexed | 2024-03-07T04:39:10Z |
| format | Journal article |
| id | oxford-uuid:d1070e11-b4d4-46b5-90c9-96942ad2eecf |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:39:10Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:d1070e11-b4d4-46b5-90c9-96942ad2eecf2022-03-27T07:54:05ZPharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d1070e11-b4d4-46b5-90c9-96942ad2eecfEnglishSymplectic Elements at Oxford2006Janssen, SRosen, DRicklis, RDionne, CLilja, HChristensen, SIsaacs, JDenmeade, SR BACKGROUND: Prostate cancer cells secrete unique proteases such as prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) that represent targets for the activation of prodrugs as systemic treatment of metastatic prostate cancer. Previously, a combinatorial peptide library was screened to identify a highly active peptide substrate for hK2. The peptide was coupled to an analog of the potent cytotoxin thapsigargin, L12ADT, to generate an hK2-activated prodrug that was efficiently hydrolyzed by purified hK2, stable to hydrolysis in human and mouse plasma in vitro and selectively toxic to hK2 producing prostate cancer cells in vitro. METHODS: In the current study, toxicology, pharmacokinetics, prodrug biodistribution, and antitumor efficacy studies were performed to evaluate the hK2-activated prodrug in vivo. RESULTS: The single intravenous maximally tolerated dose of prodrug was 6 mg/kg (i.e., 3.67 micromole/kg) which produced peak serum concentration of approximately 36 microM and had a half-life of approximately 40 min. In addition, over a 24 hr period <0.5% of free L12ADT analog was observed in plasma. The prodrug demonstrated significant antitumor effect in vivo while it was being administered, but prolonged intravenous administration was not possible due to local toxicity to tail veins. Subcutaneous administration of equimolar doses produced lower plasma AUC compared to intravenous dosing but equivalent intratumoral levels of prodrug following multiple doses. CONCLUSIONS: The hK2-activated prodrug was stable in vivo. The prodrug, however, was rapidly cleared and difficult to administer over prolonged dosing interval. Additional studies are underway to assess antitumor efficacy with prolonged administration of higher subcutaneous doses of prodrug. Second-generation hK2-activated thapsigargin prodrugs with increased half-lives and improved formulations are also under development. |
| spellingShingle | Janssen, S Rosen, D Ricklis, R Dionne, C Lilja, H Christensen, S Isaacs, J Denmeade, SR Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. |
| title | Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. |
| title_full | Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. |
| title_fullStr | Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. |
| title_full_unstemmed | Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. |
| title_short | Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. |
| title_sort | pharmacokinetics biodistribution and antitumor efficacy of a human glandular kallikrein 2 hk2 activated thapsigargin prodrug |
| work_keys_str_mv | AT janssens pharmacokineticsbiodistributionandantitumorefficacyofahumanglandularkallikrein2hk2activatedthapsigarginprodrug AT rosend pharmacokineticsbiodistributionandantitumorefficacyofahumanglandularkallikrein2hk2activatedthapsigarginprodrug AT ricklisr pharmacokineticsbiodistributionandantitumorefficacyofahumanglandularkallikrein2hk2activatedthapsigarginprodrug AT dionnec pharmacokineticsbiodistributionandantitumorefficacyofahumanglandularkallikrein2hk2activatedthapsigarginprodrug AT liljah pharmacokineticsbiodistributionandantitumorefficacyofahumanglandularkallikrein2hk2activatedthapsigarginprodrug AT christensens pharmacokineticsbiodistributionandantitumorefficacyofahumanglandularkallikrein2hk2activatedthapsigarginprodrug AT isaacsj pharmacokineticsbiodistributionandantitumorefficacyofahumanglandularkallikrein2hk2activatedthapsigarginprodrug AT denmeadesr pharmacokineticsbiodistributionandantitumorefficacyofahumanglandularkallikrein2hk2activatedthapsigarginprodrug |